retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Mounjaro: Retatrutide and Diabetes -

The FDA has issued warnings about unapproved GLP-1 drugs circulating online - counterfeit, compounded, or mislabeled as research use only. When access to legitimate GLP-1 clinical trials is limited - by geography, logistics, or site capacity - progress slows

Explore the transformative impact of GLP-1 medications on consumer behavior, food trends, and beyond

It is not a direct measure of skeletal muscle

The effectiveness of its GIP receptor antagonism is still under investigation

This hormone helps regulate blood sugar levels and induces a feeling of fullness, leading to reduced food intake

A new Phase 2 trial at Johns Hopkins testing the GLP-1 drug pegsebrenatide in progressive MS may finally explain why adults on diabetes medications for a decade show measurably slower brain shrinkage